Polymeric nanoparticles as drug carriers and controlled release implant devices

Nanoparticulates as Drug Carriers

Volumn , Issue , 2006, Pages 29-42

  Moghimi, S M ^a   Vega, E ^b   Garcia, M L ^b   Al Hanbali, O A R ^a   Rutt, K J ^a  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMERIC IMPLANTS;

CONTROLLED RELEASE; DRUG CARRIER; IMPLANT DEVICES; POLYMERIC NANOPARTICLES;

CONTROLLED DRUG DELIVERY;

EID: 84967436527     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860949074_0003     Document Type: Chapter

References (66)

1. Moghimi SM, Hunter AC and Murray JC (2005) Nanomedicine: Current status and future prospects. FASEB J 19:311-330.
2. Panyam J and Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev 55:329-347.
3. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H and Couvreur P (2003) Poly (alkyIcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Del Rev 55:519-548.
4. Soppimath KS, Aminabhavi TM, Kulkarni AR and Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Rel 70:1-20.
5. Moghimi SM, Hunter AC and Murray JC (2001) Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 53:283-318.
6. Salgueiro A, Egea MA, Espina M, Vails O and Garcia ML (2004) Stability and ocular tolerance of cyclophosphamide-loaded nanospheres. J Microencapsul 21:213-223.
7. Rabinow BE (2004) Nanosuspensions in drug delivery. Nat Rev Drug Discov 3: 785-796.
8. Moghimi SM (2002) Chemical camouflage of nanospheres with a poorly reactive surface: Towards development of stealth and target-specific nanocarriers. Biochim Biophys Acta (Mol Cell Res) 1590:131-139.
9. Porter CJH, Moghimi SM, Ilium L and Davis SS (1992) The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett 305:62-66.
10. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H and Begley DJ (2003) Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drugs to the nanoparticles. Pharm Res 20:409-416.
11. Huang G, Gao J, Hu Z, St. John JV, Ponder BC and Moro D (2004) Controlled drug release from hydrogel nanoparticle network. J Control Rel 94:303-311.
12. Panyam J, Zhou WZ, Prabha S, Sahoo SK and Labhasetwar V (2002) Rapid endolysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB J 16:1217-1226.
13. St. John JV, Moro DG, Russell-Jones GJ and McDougall J (2004) Protein release from and cellular infiltration into hydrogel nanoparticle scaffolds. 31st Annual Meeting of the Controlled Release Society, Honolulu, Hawaii, June 12-16.
14. Scholes PD, Coombes AGA, Ilium L, Davis SS, Vert M and Davies MC (1993) The preparation of sub-500 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery. J Control Rel 25:145-153.
15. Desgouilles S, Vauthier C, Bazile D, Vacus J, Grossiord JL, Veillard M and Couvreur P (2003) The design of nanoparticles obtained by solvent evaporation: A comparative study. Langmuir 19:9504-9510.
16. Niwa T, Takeuchi H, Hino T, Kunou N and Kawashima Y (1993) Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method and the drug release behavior. J Control Rel 25:89-98.
17. Quintanar-Guerrero D, Allémann E, Fessi H and Doelker E (1998) Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 24:1113-1128.
18. Bilati U, Allémann E and Doelker E (2005) Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci 24: 67-75.
19. Couvreur P, Kante M, Roland M, Guiot P, Bauduin P and Speiser P (1979) Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: Preparation, morphological and sorptive properties. J Pharm Pharmacol 31:331-332.
20. Lescure F, Zimmer C, Roy D and Couvreur P (1992) Optimization of polycyanoacrylate nanoparticle preparation: Influence of sulfur dioxide and pH on nanoparticle characteristics. J Coll Interf Sci 154:77-86.
21. De Keyser JL, Poupaert JH and Dumont P (1991) Poly(diethylmethylidenemalonate) nanoparticles as a potential drug carrier: Preparation, distribution and elimination after intravenous and peroral administration to mice. J Pharm Sci 80:67-70.
22. Jung T, Breitenbach A and Kissel T (2000) Sulfobutylated poly(vinylalcohol)-grafted-poly(lactide-co-glycolide) facilitate the preparation of small negatively charged biodegradable nanospheres for protein delivery. J Control Rel 67:157-169.
23. Wu C, Fu J and Zhao Y (2000) Novel nanoparticles formed via self-assembly of poly(ethylene glycol-b-sebacic anhydride) and their degradation in water. Macromolecules 33:9040-9043.
24. Broz P, Benito SM, Saw CL, Burger P, Heider H, Pfisterer M, Marsch S, Meier W and Hunziker P (2005) Cell targeting by a generic receptor-targeted polymer nanocontainer platform. J Control Rel 102:475-488.
25. Boudad H, Legrand P, Lebas G, Cheron M, Duchêne D and Ponchel GG (2001) Combined hydroxylpropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm 218:113-124.
26. Labib A, Lenaerts V, Chouinard F, Leroux JC, Ouellet R and van Lier JE (1991) Biodegradable nanospheres containing phthalocyanines and naphthalocyanines for targeted photodynamic tumor therapy. Pharm Res 8:1027-1031.
27. Jeong YI, Cho CS, Kim SH, Ko KS, Kim SI, Shim YH and Nah JW (2001) Preparation of poly(DL-lactide-co-glycolide) nanoparticles without surfactant. J Appl Polym Sci 80: 2228-2236.
28. Allemann E, Leroux JC, Gurnay R and Doelker E (1993) In vitro extended-release properties of drug-loaded poly(D,L-lactic) acid nanoparticles produced by a salting-out procedure. Pharm Res 10:1732-1737.
29. Randolph TW, Randolph AD, Mebes M and Yeung S (1993) Submicron-sized biodegrad-. able particles of poly(L-lactic acid) via the gas antisolvent spray precipitation process. Biotechnol Prog 9:429-435.
30. Tokumitsu H, Ichikawa H and Fuukumori Y (1999) Chitosan-gadopenteic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: Preparation by novel emulsion-droplet coalscence technique and charaterization. Pharm Res 16:1830-1835.
31. Prokop A, Kozlov E, Newman GW and Newman MJ (2002) Water-based nanoparticulate polymeric system for protein delivery: Permeability control and vaccine application. Biotechnol Bioeng 78:459-466.
32. Calvo P, Remunan-Lopez C, Vila-Jato JL and Alonso MJ (1997) Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 14:1431-1436.
33. Liu H, Finn N and Yates MZ (2005) Encapsulation and sustained release of a model drug, indomethacin, using CO2-based microencapsulation. Langmuir 21:379-385.
34. Panyam J, Williams D, Dash A, Leslie-Pelecky D and Labhasetwar V (2004) Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci 93:1804-1814.
35. Polakovic M, Gorner T, Gref R and Dellacherie E (1999) Lidocaine loaded biodegradable nanospheres. II. Modeling of drug release. J Control Rel 60:169-177.
36. Tamber H, Johansen P, Merkle HP and Gander B (2005) Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Del Rev 57: 357-376.
37. Stella B, Arpicco S, Peracchia MT, Desmaële D, Hoebeke J, Renoir M, D’Angelo J, Cattel L and Couvreur P (2000) Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci 89:1452-1464.
38. Moghimi SM, Porter CJH, Muir IS, Ilium L and Davis SS (1991) Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating. Biochem Biophys Res Commun 177:861-866.
39. Moghimi SM, Hedeman H, Ilium L and Davis SS (1993) Effect of splenic congestion associated with haemolytic anaemia on filtration of “spleen-homing” microspheres. Clin Sci 84:605-609.
40. Moghimi SM, Hedeman H, Christy NM, Ilium L and Davis SS (1993) Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats. J Leukoc Biol 54:513-517.
41. Laverman P, Carstens MG, Storm G and Moghimi SM (2001) Recognition and clearance of methoxypoly(ethyleneglycol) 2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology. Biochim Biophys Acta (General Subjects) 1526:227-229.
42. Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, Klein C, Andreux JP and Couvreur P (2002) Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 15:1317-1326.
43. Song C, Labhasetwar V, Cui X, Underwood T and Levy RJ (1998) Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: Results with an acute dog model. J Control Rel 54:201-211.
44. Moghimi SM and Bonnemain B (1999) Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: Applications in lymphoscintigraphy and indirect lymphography. Adv Drug Del Rev 37:295-312.
45. Hawley AE, Ilium L and Davis SS (1997) Lymph node localisation of biodegradable nanospheres surface modified with poloxamer and poloxamine block co-polymers. FEBS Lett 400:319-323.
46. Moghimi SM (2003) Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: The effect of the ethylene oxide chain configuration. FEBS Lett 540:241-244.
47. Moghimi SM and Rajabi-Siahboomi AR (1996) Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues. Prog Biophys Mol Biol 65:221-249.
48. Jiang W, Gupta RK, Deshpande MC and Schwendeman SP (2005) Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Del Rev 57:391-410.
49. Simecka JW (1998) Mucosal immunity of the gastrointestinal tract and oral tolerance. Adv Drug Del Rev 34:235-259.
50. Ermak TH and Giannasca PJ (1988) Microparticle targeting to M cells. Adv Drug Deliv Rev 34:261-283.
51. O’Hagan DT and Valiante NM (2003) Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2:727-735.
52. O’Hagan DT, Singh M and Ulmer JB (2004) Microparticles for delivery of DNA vaccines. Immunol Rev 199:191-200.
53. van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Verhoef JC and Junginger HE (2003) Chitosan microparticles for mucosal vaccination against diphteria: Oral and nasal efficacy studies in mice. Vaccine 21:1400-1408.
54. Takeuchi H, Yamamoto H and Kawashima YY (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Del Rev 47:39-54.
55. Carino GP, Jacob JS and Mathiowitz E (2000) Nanosphere based oral insulin delivery. J Control Rel 65:261-269.
56. Arbos P, Campanero MA, Arangoa MA, Renedo MJ and Irache JM (2003) Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Rel 89:19-30.
57. Tobio M, Sanchez A, Vila A, Soriano I, Evora C, Vila-Jato JL and Alonso MJ (2000) The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Coll Surf (B-Biointerface) 18:315-323.
58. Fresta M, Fontana C, Bucolo G, Cavallaro G, Giammona G and Puglisi G (2001) Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanospheres-encapsulated acyclovir. J Pharm Sci 90:288-297.
59. de Kozak Y, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, Naud MC, Garcia E and Couvreur P (2004) Intraocular injection of tamoxifen-loaded nanoparticles: Anew treatment of experimental autoimmune uveoretinitis. Eur J Immunol 34:3702-3712.
60. Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, Puglisi G, Lee VHL and Fresta M (2003) Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on occular drug bioavailability. Pharm Res 20:584-590.
61. Bucolo C, Maltese A, Maugeri F, Busa B, Puglisi G and Pignatello R (2004) Eudragit RL100 nanoparticle system for the opthalmic delivery of cloricromene. J Pharm Pharmacol 56:841-846.
62. Vila A, Gill H, Mccallion O and Alonso MJ (2004) Transport of PLA-PEG particles across the nasal mucosa: Effect of particle size and PEG coating density. J Control Rel 98:231-244.
63. Moghimi SM, Hunter AC, Murray JC and Szewczyk A (2004) Cellular distribution of nonionic micelles. Science 303:626-627.
64. Hunter AC and Moghimi SM (2002) Therapeutic synthetic polymers: A game of Russian roulette? Drug Discov Today 7:998-1001.
65. Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G and Szewczyk A (2005) A two-stage poly(ethylenimine)-mediated cytotoxicity: Implications for gene-transfer/therapy. Mol Ther 11:990-995.
66. Gbadamosi JK, Hunter AC and Moghimi SM (2002) PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett 532:338-344.